New drug targets dangerous fat levels in blood

NCT ID NCT03783377

Completed Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new medicine called ARO-APOC3 in healthy volunteers and people with severely high triglycerides or a rare genetic condition called familial chylomicronemia syndrome. The main goal was to check safety and how the drug moves through the body. The study involved 112 participants and has been completed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILIAL CHYLOMICRONEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial chylomicronemia syndrome familial lipoprotein lipase deficiency hypertriglyceridemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FAMILIAL CHYLOMICRONEMIA HYPERTRIGLYCERIDEMIA

Contacts and locations

Locations

Research Site 10

Papatoetoe, Auckland, 2025, New Zealand
Research Site 11

Christchurch, 8011, New Zealand
Research Site 2

Camperdown, New South Wales, 2050, Australia
Research Site 3

Adelaide, South Australia, 5000, Australia
Research Site 4

Perth, Washington, 6009, Australia
Research Site 5

Sippy Downs, Queensland, Australia
Research Site 6

Chicoutimi, Quebec, G7H 7K9, Canada
Research Site 7

London, Ontario, N6A 5B7, Canada
Research Site 8

Montreal, Quebec, H2W 1R7, Canada
Research Site 9

Grafton, Auckland, 1010, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.